Stifel Nicolaus Lowers LivaNova (NASDAQ:LIVN) Price Target to $60.00

LivaNova (NASDAQ:LIVN) had its price target decreased by stock analysts at Stifel Nicolaus from $72.00 to $60.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 46.59% from the stock’s previous close.

A number of other research firms have also weighed in on LIVN. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Mizuho reduced their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Needham & Company LLC reduced their target price on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Robert W. Baird boosted their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $64.20.

LivaNova Stock Down 1.3 %

NASDAQ:LIVN opened at $40.93 on Wednesday. LivaNova has a 1-year low of $40.37 and a 1-year high of $64.47. The company has a 50-day moving average of $47.52 and a 200 day moving average of $49.50. The firm has a market cap of $2.22 billion, a PE ratio of 97.45 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its holdings in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the period. Sterling Capital Management LLC increased its holdings in LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares during the period. Central Pacific Bank Trust Division increased its holdings in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the period. Vestcor Inc acquired a new position in LivaNova in the 4th quarter worth approximately $204,000. Finally, Optimize Financial Inc acquired a new position in LivaNova in the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.